Here, we demonstrate that c-Maf deletion suppressed the development of not only hyperglycemia and hyperfiltration but also diabetic nephropathy, similar to the treatment with SGLT2 inhibitors in mice (40–43). Here, MAF is linked to diabetic kidney disease.